Philips Can Recover From Its Health Crisis

[ad_1] The European medical-technology supplier is starting to emerge from a torrid period marked by the recall of machines for treating sleep apnea. [ad_2] Source link

Exor Buys 15% Stake in Philips

[ad_1] Exor has taken a 15% stake in Philips for an undisclosed sum but worth around €2.6 billion and will be able to nominate one board member. [ad_2] Source link

Family of Henrietta Lacks, Whose Unique Cells Changed Science, Settles With Thermo Fisher

[ad_1] What to Read Next [ad_2] Source link

Baxter Selling Biopharma-Solutions Arm for $4.25 Billion

[ad_1] The sale to private-equity firms Advent International and Warburg Pincus comes as the medical-products company streamlines its focus. [ad_2] Source link

Medical Device Maker Stryker Faces New Bribery Concerns

[ad_1] Medical-device maker Stryker disclosed an investigation by U.S. authorities into potential violations of antibribery law, the third such probe into the company in the past decade. [ad_2] Source link

Royal Philips 1Q Net Loss Widened on Litigation Costs

[ad_1] Royal Philips reported a loss for the first quarter of €655 million after booking a provision related to a class action in the U.S., and added uncertainties remained for…

The Return-to-Normal Healthcare Trade Picks Up Pace

[ad_1] Healthcare is finally getting back to normal, which is good news for medical-device makers and hospitals, but not for insurers. [ad_2] Source link

WSJ News Exclusive | A $22 Million South Carolina Estate Includes a Horse Barn, a Pub-Style Bar and a Kangaroo Named Irwin

[ad_1] Be the first to know about the biggest and best luxury home sales and listings by signing up for  our Mansion Deals email alert. An estate asking $22 million…

Health Care Roundup: Market Talk

[ad_1] Find insight on Bluebird Bio, Johnson & Johnson and more in the latest Market Talks covering the Health Care sector. [ad_2] Source link

Medtronic Isn’t Out of the Woods Yet

[ad_1] Markets Heard on the Street Medtronic’s financial results were positive, but the company has more to do to convince investors of its growth path [ad_2] Source link